HOME >> MEDICINE >> NEWS
Acrux completes enrollment in key phase 2 trial

Melbourne, Australia, 2 May 2007: Drug delivery company Acrux (ASX: ACR), announced today that it has successfully completed enrolment of 40 patients in the final Phase 2 trial of its unique testosterone lotion for treatment of testosterone deficiency in men. Preliminary results of the trial are expected to be available in July 2007.

The trial is being conducted at 8 clinics in the USA. The aim is to demonstrate that discreet daily application of Acrux's user-friendly lotion to the armpits raises the level of testosterone into the normal range. This is being undertaken by measuring testosterone levels in the blood and does not require the measurement of clinical symptoms.

A Phase 3 trial in 150-200 patients will be required before marketing applications can be made to regulatory authorities. This trial is expected to commence in early 2008 and will again require the measurement of testosterone levels in the blood, rather than the impact on clinical symptoms.

Acrux CEO Richard Treagus commented "Our Phase 2 study will complete on time and the remaining requirements to get this compelling product on the market are relatively straightforward. Confidence in the value of our Testosterone MD-Lotion has been further boosted by the interest shown in this product by potential licensing partners."

About Acrux's Testosterone MD-Lotion

Market research in the USA amongst both patients and prescribers that use current testosterone replacement products, including gels and injections, showed a strong preference by the patients for daily application of Acrux's lotion over the existing products. The Acrux product will apply a precise dose of quick-drying lotion to the armpit once daily, via a convenient and ergonomic "no-touch" applicator.

The leading gel is applied each day as a 5 gram dose by hand to the shoulders, upper arms and/or abdomen. It takes longer to dry and patients are advised
'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-417-520-509
Research Australia
1-May-2007


Page: 1 2

Related medicine news :

1. Acrux and Oreganon further expand their collaboration
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
8. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
9. GroPep completes final milestone of the path malaria vaccine initiative
10. Im a Kid Too project completes first phase
11. Worlds largest respiratory health study launches next phase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/11/2019)... BURLINGTON, Mass. (PRWEB) , ... September 11, 2019 , ... ... it is sponsoring the registration table at the annual St. Jude Walk/Run Boston. To ... to bring thousands of participants to raise a goal of $650,000 for St. ...
(Date:9/9/2019)... (PRWEB) , ... September 09, 2019 , ... ... and Haines Advanced Dentistry in Cornelius, NC, now welcome individuals with tooth loss ... dentists frequently work with patients who have single or multiple missing teeth and ...
(Date:9/9/2019)... ... September 09, 2019 , ... Cardinal Park Family Dental ... decades and counting. The practice offers family dentistry , laser gum disease treatment, ... year marks the 20th year that Cardinal Park Family Dental Care has provided state-of-the-art, ...
(Date:9/9/2019)... (PRWEB) , ... September 09, 2019 , ... ... unanimously to adopt an organization-wide policy focusing on a diabetes-language movement (#LanguageMatters) to ... that is neutral and non-judgmental, free from stigma, respectful and inclusive, empowering, and ...
(Date:9/8/2019)... ... ... Stetson University ranks No. 5 on U.S. News & World ... addition, Stetson appears on five additional lists in the same category: Best Undergraduate Teaching, ... Diversity, No. 34; and a new list this year, Top Performers on Social Mobility, ...
Breaking Medicine News(10 mins):
(Date:9/11/2019)... ... 11, 2019 , ... LifePod® Solutions Inc., the ... LifePod’s voice-first service for rollout to an initial 100 HomeThrive customers. With over ... 50, demand has steadily increased for solutions that both enable loved ones to ...
(Date:9/11/2019)... ... September 11, 2019 , ... Genedata, the leading ... globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D ... , “As part of our strategy to expand our biopharmaceutical R&D operations, ...
(Date:9/11/2019)... ... September 11, 2019 , ... Alain Gazaui, ... of medical spa treatment approvals, will be speaking on emerging markets and telehealth ... October 2-4, 2019 in Silicon Valley. , Gazaui brings an extensive history in ...
Breaking Medicine Technology:
Cached News: